PEPG · Insider Trading
PepGen Inc. Common Stock
Every open-market purchase and sale reported by PEPG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-22 | Habib J Dable | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Laurie Keating | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Howard Mayer | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Lisa Wyman | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Joshua Resnick | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Mitchell H. Finer | Director | A | +34,000 deriv. | — |
| 2026-06-22 | Heidi Henson | Director | A | +34,000 deriv. | — |
| 2026-06-22 | RA Capital Nexus Fund II, L.P. | Director | A | +34,000 deriv. | — |
| 2026-05-26 | Kasra Kasraian | Chief Technical Officer | Sell | −1,233 | −$1.74K |
| 2026-03-06 | Noel Donnelly | Chief Financial Officer | Sell | −2,084 | −$12.99K |
| 2026-03-06 | Paul Streck | EVP, Head of R&D | Sell | −1,879 | −$11.71K |
| 2026-03-06 | James G McArthur | President and CEO | Sell | −5,275 | −$32.88K |
| 2026-03-02 | Kasra Kasraian | Chief Technical Officer | A | +34,557 | — |
| 2026-03-02 | Noel Donnelly | Chief Financial Officer | A | +76,793 | — |
| 2026-03-02 | Paul Streck | EVP, Head of R&D | A | +50,300 | — |
| 2026-03-02 | Joseph Vittiglio | Chief Business & Legal Officer | A | +30,717 | — |
| 2026-03-02 | James G McArthur | President and CEO | A | +187,688 | — |
| 2025-12-18 | Noel Donnelly | Chief Financial Officer | MIXED | — | — |
| 2025-12-18 | Paul Streck | EVP, Head of R&D | MIXED | — | — |
| 2025-12-18 | James G McArthur | President and CEO | MIXED | — | — |
| 2025-12-10 | Joseph Vittiglio | Chief Business & Legal Officer | A | +35,000 | — |
| 2025-10-01 | Oxford Science Enterprises plc | — | Buy | +200,000 | +$640.00K |
| 2025-09-30 | RA Capital Healthcare Fund LP | Director | Buy | +9,375,000 | +$30.00M |
| 2025-06-06 | Heidi Henson | Director | A | +16,000 deriv. | — |
| 2025-06-06 | Howard Mayer | Director | A | +16,000 deriv. | — |
| 2025-06-06 | Joshua Resnick | Director | A | +16,000 deriv. | — |
| 2025-06-06 | Laurie Keating | Director | A | +16,000 deriv. | — |
| 2025-06-06 | Habib J Dable | Director | A | +16,000 deriv. | — |
| 2025-06-06 | RA Capital Nexus Fund II, L.P. | Director | A | +16,000 deriv. | — |
| 2025-06-02 | Paul Streck | EVP, Head of R&D | Buy | +8,375 | +$10.39K |
| 2025-05-21 | Kasra Kasraian | Chief Technical Officer | A | +16,750 | — |
| 2025-04-22 | James G McArthur | President and CEO | Buy | +10,000 | +$13.55K |
| 2025-04-09 | James G McArthur | President and CEO | Buy | +41,500 | +$47.72K |
| 2025-03-31 | Mitchell H. Finer | Director | A | +26,000 deriv. | — |
| 2025-03-31 | Lisa Wyman | Director | A | +26,000 deriv. | — |
| 2025-03-05 | Paul Streck | EVP, Head of R&D | A | +19,430 | — |
| 2025-03-05 | Mary Beth DeLena | General Counsel | A | +13,400 | — |
| 2025-03-05 | Noel Donnelly | Chief Financial Officer | A | +23,283 | — |
| 2025-03-05 | James G McArthur | President and CEO | A | +60,719 | — |
| 2025-02-26 | Noel Donnelly | Chief Financial Officer | MIXED | +1,673 | −$2.57K |
| 2025-02-26 | Mary Beth DeLena | General Counsel | MIXED | +1,568 | −$2.41K |
| 2024-08-20 | Paul Streck | EVP, Head of R&D | A | +242,816 deriv. | — |
| 2024-07-26 | Michelle L Mellion | Chief Medical Officer | MIXED | — | −$61.01K |
| 2024-07-19 | Michelle L Mellion | Chief Medical Officer | MIXED | — | −$100.90K |
| 2024-07-16 | Michelle L Mellion | Chief Medical Officer | MIXED | — | −$71.76K |
| 2024-07-03 | Michelle L Mellion | Chief Medical Officer | MIXED | — | −$7.12K |
| 2024-06-26 | Michelle L Mellion | Chief Medical Officer | MIXED | — | −$73.88K |
| 2024-06-21 | Joshua Resnick | Director | A | +13,000 deriv. | — |
| 2024-06-21 | Habib J Dable | Director | A | +13,000 deriv. | — |
| 2024-06-21 | Howard Mayer | Director | A | +8,667 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Oxford Science Enterprises plc | 10%+ Owner | 4,955,388 | $12.09M |
| James G McArthur | President and CEO | 296,326 | $723.04K |
| RA Capital Healthcare Fund LP | Director | 207,672 | $506.72K |
| Noel Donnelly | Chief Financial Officer | 111,655 | $272.44K |
| Paul Streck | EVP, Head of R&D | 76,226 | $185.99K |
| Joseph Vittiglio | Chief Business & Legal Officer | 65,717 | $160.35K |
| Kasra Kasraian | Chief Technical Officer | 50,074 | $122.18K |
| Mary Beth DeLena | General Counsel | 14,968 | $36.52K |
| Laurie Keating | Director | 4,166 | $10.17K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PEPG quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.